PKM and lung adenocarcinoma: Our results suggest that 18F-FDG PET can be used to predict PKM2 status, and that 18F-FDG PET may help determine the therapeutic strategy for lung adenocarcinoma patients by predicting tumor response to PKM2-targeted therapies.